Literature DB >> 13678574

Recent Insights into HIV Accessory Proteins.

Jenny L. Anderson1, Thomas J. Hope.   

Abstract

HIV produces structural, regulatory, and accessory proteins during viral replication in host cells. The accessory proteins include Nef, viral infectivity factor (Vif), viral protein R, and viral protein U or viral protein X. Although these accessory proteins are generally dispensable for viral replication in vitro, they are essential for viral pathogenesis in vivo. Consequently, there has been much interest in understanding how these accessory proteins function because this research may yield new antiviral targets to curb HIV pathogenesis in vivo. Therefore, this review highlights recent advances in understanding the HIV accessory proteins and emphasizes breakthrough insights into the elusive Vif protein and potential new targets for therapeutic intervention.

Entities:  

Year:  2003        PMID: 13678574     DOI: 10.1007/s11908-003-0024-8

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  99 in total

1.  HIV-1 RNA editing, hypermutation, and error-prone reverse transcription.

Authors:  B Berkhout; A T Das; N Beerens
Journal:  Science       Date:  2001-04-06       Impact factor: 47.728

2.  Role of the non-homologous DNA end joining pathway in the early steps of retroviral infection.

Authors:  L Li; J M Olvera; K E Yoder; R S Mitchell; S L Butler; M Lieber; S L Martin; F D Bushman
Journal:  EMBO J       Date:  2001-06-15       Impact factor: 11.598

3.  The tyrosine kinase Hck is an inhibitor of HIV-1 replication counteracted by the viral vif protein.

Authors:  G Hassaïne; M Courcoul; G Bessou; Y Barthalay; C Picard; D Olive; Y Collette; R Vigne; E Decroly
Journal:  J Biol Chem       Date:  2001-02-27       Impact factor: 5.157

Review 4.  Insights into the biology of HIV-1 viral protein R.

Authors:  Michael P Sherman; Carlos M C De Noronha; Samuel A Williams; Warner C Greene
Journal:  DNA Cell Biol       Date:  2002-09       Impact factor: 3.311

5.  Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection.

Authors:  F Kirchhoff; T C Greenough; D B Brettler; J L Sullivan; R C Desrosiers
Journal:  N Engl J Med       Date:  1995-01-26       Impact factor: 91.245

6.  Association of Vpu-binding protein with microtubules and Vpu-dependent redistribution of HIV-1 Gag protein.

Authors:  M A Handley; S Paddock; A Dall; A T Panganiban
Journal:  Virology       Date:  2001-12-20       Impact factor: 3.616

7.  Docking of HIV-1 Vpr to the nuclear envelope is mediated by the interaction with the nucleoporin hCG1.

Authors:  Erwann Le Rouzic; Aurélie Mousnier; Cecilia Rustum; Françoise Stutz; Einar Hallberg; Catherine Dargemont; Serge Benichou
Journal:  J Biol Chem       Date:  2002-09-12       Impact factor: 5.157

8.  The leader of human immunodeficiency virus type 1 genomic RNA harbors an internal ribosome entry segment that is active during the G2/M phase of the cell cycle.

Authors:  Ann Brasey; Marcelo Lopez-Lastra; Theophile Ohlmann; Nancy Beerens; Ben Berkhout; Jean-Luc Darlix; Nahum Sonenberg
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

9.  An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein.

Authors:  N Madani; D Kabat
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

10.  Visualization of the intracellular behavior of HIV in living cells.

Authors:  David McDonald; Marie A Vodicka; Ginger Lucero; Tatyana M Svitkina; Gary G Borisy; Michael Emerman; Thomas J Hope
Journal:  J Cell Biol       Date:  2002-11-04       Impact factor: 10.539

View more
  2 in total

Review 1.  HIV accessory proteins and surviving the host cell.

Authors:  Jenny L Anderson; Thomas J Hope
Journal:  Curr HIV/AIDS Rep       Date:  2004-04       Impact factor: 5.071

2.  Disruption of the actin cytoskeleton can complement the ability of Nef to enhance human immunodeficiency virus type 1 infectivity.

Authors:  Edward M Campbell; Rafael Nunez; Thomas J Hope
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.